Company news
Nektar Therapeutics news in 2022
Nektar Therapeutics's news releases, calls and decks from 2022, newest first.
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
December 11, 2022
Nektar Therapeutics to Host Investor & Analyst Event on December 12th
December 4, 2022
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 9, 2022
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
November 8, 2022
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
November 2, 2022
Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
October 24, 2022
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
September 6, 2022
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
August 15, 2022
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets
July 25, 2022
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
June 30, 2022
Nektar Therapeutics Reports First Quarter 2022 Financial Results
May 4, 2022
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
April 24, 2022
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
April 22, 2022
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
April 21, 2022
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
April 13, 2022
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial
March 13, 2022
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
March 13, 2022
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
February 27, 2022
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets
February 16, 2022
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
January 4, 2022